Related content

The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts

By Breistol K.   Hendriks H.R.   Berger D.P.   Langdon S.P.   Fiebig H.H.   Fodstad O.  

European Journal of Cancer, Vol. 34, Iss. 10, 1998-09 ,pp. : 1602-1606

Elsevier

Access to resources Recommend Favorite

Enhancement of Antitumour Activity of Cisplatin by N,N-Diethyl-2-[4-(Phenylmethyl)Phenoxy] Ethanamine.HCl in Human Ovarian Cancer Cells with Intrinsic or Acquired Resistance to Cisplatin

By Kudoh K.   Kikuchi Y.   Hiramatsu H.   Hirata J.   Yamamoto K.   Kita T.   Nagata I.  

European Journal of Cancer, Vol. 33, Iss. 1, 1997-01 ,pp. : 122-128

Elsevier

Access to resources Recommend Favorite

Novel pyrimidine-2,4-diamine derivative suppresses the cell viability and spindle assembly checkpoint activity by targeting Aurora kinases

By Salmela Anna-Leena   Pouwels Jeroen   Mäki-Jouppila Jenni   Kohonen Pekka   Toivonen Pauliina   Kallio Lila   Kallio Marko  

Carcinogenesis, Vol. 34, Iss. 2, 2013-02 ,pp. : 436-445

Oxford University Press

Access to resources Recommend Favorite

Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-l-aspartate in murine colon carcinoma no. 26

By Van Laar J.A.M.   Mayhew E.G.   Cao S.   Durrani F.A.   Peters G.J.   Rustum Y.M.  

European Journal of Cancer, Vol. 31, Iss. 6, 1995-06 ,pp. : 974-976

Elsevier

Access to resources Recommend Favorite

Therapy of rat tracheal carcinoma IC-12 in SCID mice - vascular targeting with [ 213 Bi]-MAb TES-23

By Kennel S.J.   Lankford T.   Davern S.   Foote L.   Taniguchi K.   Ohizumi I.   Tsutsumi Y.   Nakagawa S.   Mayumi T.   Mirzadeh S.  

European Journal of Cancer, Vol. 38, Iss. 9, 2002-06 ,pp. : 1278-1287

Elsevier

Access to resources Recommend Favorite